Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD
- Written by PR Newswire
ADELAIDE, Australia, Feb. 17, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5) (Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (EmpathBio), a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences (atai)....
